Lung Cancer News and Research

Latest Lung Cancer News and Research

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

EZH2 protein may aid prognostication in resected NSCLC

A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe.

30 Oct 2013

ATS and ACCP release five recommendations for tests, procedures in pulmonary medicine

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation's Choosing Wisely® campaign, was produced by a collaborative task force assembled by the American Thoracic Society (ATS) and the American College of Chest Physicians (ACCP).

30 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Janssen submits Marketing Authorization Application for Ibrutinib

Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.

30 Oct 2013

New ex-smokers across Cheshire and Merseyside celebrate first steps towards a smokefree life

Over 9,000 people across Cheshire and Merseyside joined a quarter of a million people in the UK choosing to turn their back on cigarettes this month in the mass 28-day stop smoking challenge, Stoptober. In Merseyside, 7187 people signed up along with 1,288 people in Cheshire West and Chester.

30 Oct 2013

New pulmonary medicine list includes five recommendations to improve patient care and outcomes

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation’s Choosing Wisely campaign, was produced by a collaborative task force assembled by the American Thoracic Society and the American College of Chest Physicians.

30 Oct 2013

Penn Medicine researchers show predictive power of overlooked lymph nodes

For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have shown the predictive power of a group of overlooked lymph nodes--known as the posterior intercostal lymph nodes--that could serve as a better tool to stage and ultimately treat patients with malignant pleural mesothelioma.

29 Oct 2013

Loyola hospital uses new 3-D vision technology for minimally invasive lung surgery

Loyola University Medical Center is the first Illinois hospital to use new 3-D vision technology for minimally invasive lung surgery.

29 Oct 2013

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT-, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer.

29 Oct 2013

Complement protein holds diagnostic, prognostic promise in lung cancer

A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests.

28 Oct 2013

Current drugs may harbor small-cell lung cancer promise

Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease.

28 Oct 2013

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat. Results were presented at the 15th World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Leukemia drug reverses symptoms of colitis in lab tests

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta.

24 Oct 2013

MEDIAN Technologies announces participation in World Conference on Lung Cancer

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, today announced its participation in the World Conference on Lung Cancer, to be held October 27-30, in Sydney, Australia.

24 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

IBM joins with University Hospital Zurich to test new prototype tool for diagnosing cancer

IBM scientists are collaborating with pathologists at the University Hospital Zurich to test a new prototype tool to accurately diagnose different types of cancer. This work is based on a technology developed by IBM scientists called a microfluidic probe, which slightly resembles the nib of a fountain pen.

23 Oct 2013

Lung Cancer News and Research

Latest Lung Cancer News and Research

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

EZH2 protein may aid prognostication in resected NSCLC

ATS and ACCP release five recommendations for tests, procedures in pulmonary medicine

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Janssen submits Marketing Authorization Application for Ibrutinib

New ex-smokers across Cheshire and Merseyside celebrate first steps towards a smokefree life

New pulmonary medicine list includes five recommendations to improve patient care and outcomes

Penn Medicine researchers show predictive power of overlooked lymph nodes

Loyola hospital uses new 3-D vision technology for minimally invasive lung surgery

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

Complement protein holds diagnostic, prognostic promise in lung cancer

Current drugs may harbor small-cell lung cancer promise

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Leukemia drug reverses symptoms of colitis in lab tests

MEDIAN Technologies announces participation in World Conference on Lung Cancer

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

IBM joins with University Hospital Zurich to test new prototype tool for diagnosing cancer

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in